Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 36

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
 stock, net of issuance costs (Note 6c) 
     32,574  
     326  
     574,743  
     -  
     575,069 
  
    Stock-based compensation 
     -  
     -  
     180,763  
     -  
     180,763 
  
    Net loss 
     -  
     -  
     -  
     (5,228,919) 
     (5,228,919)
  
    Balance, June 30, 2025 
     604,963  
    $6,050  
    $68,521,126  
    $(70,200,532) 
    $(1,673,356)
  
    Balance 
     604,963  
    $6,050  
    $68,521,126  
    $(70,200,532) 
    $(1,673,356)

*Retroactively restated
for one-for-twenty-eight share consolidation on June 27, 2025.

See
accompanying notes to the unaudited condensed consolidated financial statements

F-3

INDAPTUS
THERAPEUTICS, INC.

Unaudited
Condensed Consolidated Statements of Cash Flows

    2025  
    2024 

    For the Six Months Ended 

    June 30, 

    2025  
    2024 
  
    Cash flows from operating activities: 

    Net loss 
    $(9,761,349) 
    $(7,821,944)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation 
     -  
     735 
  
    Stock-based compensation 
     421,654  
     1,557,543 
  
    Change in fair value of convertible promissory notes 
     787,703  
     - 
  
    Changes in operating assets and liabilities: 

    Prepaid expenses and other current assets 
     821,899  
     696,430 
  
    Accounts payable and other current liabilities 
     (1,334,030) 
     (847,502)
  
    Operating lease right-of-use asset and liability, net 
     (1,193) 
     325